[
  {
    "ts": null,
    "headline": "Stocks to Watch Recap: AMD, Eli Lilly, EchoStar, Trump Media",
    "summary": "↗️ Advanced Micro Devices (AMD): The semiconductor powerhouse said it would collaborate with IBM (IBM) to develop next-generation computing architecture. AMD shares rose 2% Tuesday. ↗️Trump Media & Technology (DJT): President Trump’s media business is launching a new company to buy and hold a niche token affiliated with Crypto.",
    "url": "https://finnhub.io/api/news?id=276a61c9546c3fa44b0408d5651055406c79ae0be5748701c54dca2a6f569583",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756244696,
      "headline": "Stocks to Watch Recap: AMD, Eli Lilly, EchoStar, Trump Media",
      "id": 136536307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️ Advanced Micro Devices (AMD): The semiconductor powerhouse said it would collaborate with IBM (IBM) to develop next-generation computing architecture. AMD shares rose 2% Tuesday. ↗️Trump Media & Technology (DJT): President Trump’s media business is launching a new company to buy and hold a niche token affiliated with Crypto.",
      "url": "https://finnhub.io/api/news?id=276a61c9546c3fa44b0408d5651055406c79ae0be5748701c54dca2a6f569583"
    }
  },
  {
    "ts": null,
    "headline": "Equities Rise as Traders Brush Aside Trump-Cook Row, Await Nvidia Earnings",
    "summary": "US equities rose Tuesday as traders appeared to look past President Donald Trump's move to remove Fe",
    "url": "https://finnhub.io/api/news?id=0db052e602af28d9262e01de40134635683edd244352e4641828f6e71236d665",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756242534,
      "headline": "Equities Rise as Traders Brush Aside Trump-Cook Row, Await Nvidia Earnings",
      "id": 136536308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US equities rose Tuesday as traders appeared to look past President Donald Trump's move to remove Fe",
      "url": "https://finnhub.io/api/news?id=0db052e602af28d9262e01de40134635683edd244352e4641828f6e71236d665"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Trounced the Market on Tuesday",
    "summary": "The pharma giant advanced a medication that could be extremely competitive in a high-profile segment.",
    "url": "https://finnhub.io/api/news?id=aa7d8691107520bbeecafe7b51b50fe72362ec5868d0aa4dd4574a6b667a03cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756241175,
      "headline": "Why Eli Lilly Stock Trounced the Market on Tuesday",
      "id": 136536309,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharma giant advanced a medication that could be extremely competitive in a high-profile segment.",
      "url": "https://finnhub.io/api/news?id=aa7d8691107520bbeecafe7b51b50fe72362ec5868d0aa4dd4574a6b667a03cb"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: EchoStar, AT&T, AMD, Lilly, Boeing, DJT, Talen, Semtech, and More",
    "summary": "AT&T intends to buy spectrum licenses from EchoStar for $23 billion, while shares of Advanced Micro Devices receive an upgrade.",
    "url": "https://finnhub.io/api/news?id=e49e3e193fe6e1c6229b40766cb31e574e11f93ce654fc16950e757d655e34c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756241160,
      "headline": "These Stocks Moved the Most Today: EchoStar, AT&T, AMD, Lilly, Boeing, DJT, Talen, Semtech, and More",
      "id": 136536310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AT&T intends to buy spectrum licenses from EchoStar for $23 billion, while shares of Advanced Micro Devices receive an upgrade.",
      "url": "https://finnhub.io/api/news?id=e49e3e193fe6e1c6229b40766cb31e574e11f93ce654fc16950e757d655e34c7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly stock rises after weight loss pill passes key test",
    "summary": "Shares of Eli Lilly (LLY) closed nearly 6% higher on Tuesday after the company announced its obesity pill, orforglipron, \"met the primary and all key secondary endpoints\" in its phase 3 trial. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports the details in the video above. She also discusses President Trump's comments on drug prices. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=1523c3f0bbb5209b56dc63eeb6f28d5a790b2b39997c38897cdd46c5737b4add",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756240762,
      "headline": "Eli Lilly stock rises after weight loss pill passes key test",
      "id": 136536311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Eli Lilly (LLY) closed nearly 6% higher on Tuesday after the company announced its obesity pill, orforglipron, \"met the primary and all key secondary endpoints\" in its phase 3 trial. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports the details in the video above. She also discusses President Trump's comments on drug prices. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=1523c3f0bbb5209b56dc63eeb6f28d5a790b2b39997c38897cdd46c5737b4add"
    }
  },
  {
    "ts": null,
    "headline": "US Equity Indexes Rise as Investors Turn to Tech Heavyweights Amid Trump's Move to Oust Fed Governor",
    "summary": "US equity indexes rose at the close of trading on Tuesday, with investors seeking refuge in mega-cap",
    "url": "https://finnhub.io/api/news?id=1cdf32f0168f9fa029b8b076fb8f63d0f8f3361a4d91bb8bd583ebc7128d9a07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756240260,
      "headline": "US Equity Indexes Rise as Investors Turn to Tech Heavyweights Amid Trump's Move to Oust Fed Governor",
      "id": 136536197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US equity indexes rose at the close of trading on Tuesday, with investors seeking refuge in mega-cap",
      "url": "https://finnhub.io/api/news?id=1cdf32f0168f9fa029b8b076fb8f63d0f8f3361a4d91bb8bd583ebc7128d9a07"
    }
  },
  {
    "ts": null,
    "headline": "Lilly obesity-pill trial results find a warmer reception on Wall Street this time around",
    "summary": "Lilly obesity-pill trial results find a warmer reception on Wall Street this time around",
    "url": "https://finnhub.io/api/news?id=7d31d58132bcb7e98d93122f3aab7b5ab8a9ce7bdb3bd7e7c55a3e4f7e23d44e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756233480,
      "headline": "Lilly obesity-pill trial results find a warmer reception on Wall Street this time around",
      "id": 136541726,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Lilly obesity-pill trial results find a warmer reception on Wall Street this time around",
      "url": "https://finnhub.io/api/news?id=7d31d58132bcb7e98d93122f3aab7b5ab8a9ce7bdb3bd7e7c55a3e4f7e23d44e"
    }
  },
  {
    "ts": null,
    "headline": "Equities Rise Intraday Amid Trade Developments, Trump's Move to Fire Fed Governor",
    "summary": "US benchmark equity indexes were higher intraday as investors tracked trade developments and Preside",
    "url": "https://finnhub.io/api/news?id=9160fb57b51e3595c1bbe7d0113e7bbbe68ab089fb0ad8f840340de5b0e3984d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756232565,
      "headline": "Equities Rise Intraday Amid Trade Developments, Trump's Move to Fire Fed Governor",
      "id": 136530060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes were higher intraday as investors tracked trade developments and Preside",
      "url": "https://finnhub.io/api/news?id=9160fb57b51e3595c1bbe7d0113e7bbbe68ab089fb0ad8f840340de5b0e3984d"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Obesity Pill Trial Sparks Investor Buzz as $95B Market Race Heats Up",
    "summary": "Lilly's Obesity Pill Trial Sparks Investor Buzz as $95B Market Race Heats Up",
    "url": "https://finnhub.io/api/news?id=d481c3669b84a2b33fc1c61f0b11b4660aae01c985da6bbae915415ae10df1ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756231679,
      "headline": "Lilly's Obesity Pill Trial Sparks Investor Buzz as $95B Market Race Heats Up",
      "id": 136530061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's Obesity Pill Trial Sparks Investor Buzz as $95B Market Race Heats Up",
      "url": "https://finnhub.io/api/news?id=d481c3669b84a2b33fc1c61f0b11b4660aae01c985da6bbae915415ae10df1ea"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Up as Eli Lilly Sees Progress on Obesity Pill -- Health Care Roundup",
    "summary": "Health Care Up as Eli Lilly Sees Progress on Obesity Pill -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=1847e5b64c538d6c9717ca025a8f54ead593339e2c6795e7c2e86654a969c5f0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756231200,
      "headline": "Health Care Up as Eli Lilly Sees Progress on Obesity Pill -- Health Care Roundup",
      "id": 136541727,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Health Care Up as Eli Lilly Sees Progress on Obesity Pill -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=1847e5b64c538d6c9717ca025a8f54ead593339e2c6795e7c2e86654a969c5f0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Advances Obesity Drug Orforglipron With Positive Phase 3 Results",
    "summary": "Eli Lilly (LLY) announced positive results from the Phase 3 ATTAIN-2 trial for orforglipron, a potential treatment for obesity and type 2 diabetes, achieving key endpoints such as significant weight loss. Additionally, a clinical supply agreement with Immuneering for olomorasib, targeting lung cancer, marks continued innovation. Despite these promising advancements, LLY traded flat over the last week, aligning with broader market trends, as the overall market performance remained steady...",
    "url": "https://finnhub.io/api/news?id=5bd64cf84046796abaaaf204bd6942190fb676e5a5948d3b6eb5d107c29f6f09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756229960,
      "headline": "Eli Lilly (LLY) Advances Obesity Drug Orforglipron With Positive Phase 3 Results",
      "id": 136530062,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) announced positive results from the Phase 3 ATTAIN-2 trial for orforglipron, a potential treatment for obesity and type 2 diabetes, achieving key endpoints such as significant weight loss. Additionally, a clinical supply agreement with Immuneering for olomorasib, targeting lung cancer, marks continued innovation. Despite these promising advancements, LLY traded flat over the last week, aligning with broader market trends, as the overall market performance remained steady...",
      "url": "https://finnhub.io/api/news?id=5bd64cf84046796abaaaf204bd6942190fb676e5a5948d3b6eb5d107c29f6f09"
    }
  },
  {
    "ts": null,
    "headline": "LLY: Eli Lilly Stock Jumps on Breakthrough Obesity and Diabetes Trial Data",
    "summary": "Wall Street Pushes Lilly Higher After Obesity Drug Trial Milestone",
    "url": "https://finnhub.io/api/news?id=6c371206fc5578ad4037f2952ce51b06da8bd4c6edeeb1c7760fad55bed40f1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756228763,
      "headline": "LLY: Eli Lilly Stock Jumps on Breakthrough Obesity and Diabetes Trial Data",
      "id": 136530063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wall Street Pushes Lilly Higher After Obesity Drug Trial Milestone",
      "url": "https://finnhub.io/api/news?id=6c371206fc5578ad4037f2952ce51b06da8bd4c6edeeb1c7760fad55bed40f1a"
    }
  },
  {
    "ts": null,
    "headline": "US Equity Indexes Mixed as Trump's Order to Remove Fed Governor Hits Risk Sentiment Ahead of Nvidia Results",
    "summary": "US equity indexes searched for direction as investors weighed President Donald Trump's order to remo",
    "url": "https://finnhub.io/api/news?id=f1eb78d1ffa4cda0a2fa4cbb981642641dbd1eb7328900937e90068948936d4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756228494,
      "headline": "US Equity Indexes Mixed as Trump's Order to Remove Fed Governor Hits Risk Sentiment Ahead of Nvidia Results",
      "id": 136529931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US equity indexes searched for direction as investors weighed President Donald Trump's order to remo",
      "url": "https://finnhub.io/api/news?id=f1eb78d1ffa4cda0a2fa4cbb981642641dbd1eb7328900937e90068948936d4e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Latest Weight-Loss Pill Study Paves Way for Regulatory Approval",
    "summary": "Eli Lilly (LLY) on Tuesday disclosed another set of late-stage trial data of its investigational wei",
    "url": "https://finnhub.io/api/news?id=e0574b9faa10f09502939d14d2cf285630721c2f4039d4b39991ea5944d33a32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756226840,
      "headline": "Eli Lilly's Latest Weight-Loss Pill Study Paves Way for Regulatory Approval",
      "id": 136530065,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) on Tuesday disclosed another set of late-stage trial data of its investigational wei",
      "url": "https://finnhub.io/api/news?id=e0574b9faa10f09502939d14d2cf285630721c2f4039d4b39991ea5944d33a32"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s obesity pill is ready to ask for global approval",
    "summary": "Eli Lilly’s trial testing its obesity pill found that the highest dose of the drug lowered participants weight by 10.5%",
    "url": "https://finnhub.io/api/news?id=51e61fc2ba147af2690c41516abb010ddc374df09970d051a89f9341e0a81fc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756225638,
      "headline": "Eli Lilly’s obesity pill is ready to ask for global approval",
      "id": 136530066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s trial testing its obesity pill found that the highest dose of the drug lowered participants weight by 10.5%",
      "url": "https://finnhub.io/api/news?id=51e61fc2ba147af2690c41516abb010ddc374df09970d051a89f9341e0a81fc5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's 'Surprising Development' In Obesity Just Slammed Novo Stock",
    "summary": "Eli Lilly's 'Surprising Development' In Obesity Just Slammed Novo Stock",
    "url": "https://finnhub.io/api/news?id=550243a985b4da36f6f52a850f224dc64bc7cbebc040c785480f92433611d70f",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756224533,
      "headline": "Eli Lilly's 'Surprising Development' In Obesity Just Slammed Novo Stock",
      "id": 136541705,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Eli Lilly's 'Surprising Development' In Obesity Just Slammed Novo Stock",
      "url": "https://finnhub.io/api/news?id=550243a985b4da36f6f52a850f224dc64bc7cbebc040c785480f92433611d70f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises. Its Pill Has Ramped Up the Weight-Loss War With Novo Nordisk.",
    "summary": "Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting.’",
    "url": "https://finnhub.io/api/news?id=1a9087e480f1fd4d14b6829d74dce39e19fd049a89b042bad7a3a286749b12c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756218120,
      "headline": "Eli Lilly Stock Rises. Its Pill Has Ramped Up the Weight-Loss War With Novo Nordisk.",
      "id": 136526740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting.’",
      "url": "https://finnhub.io/api/news?id=1a9087e480f1fd4d14b6829d74dce39e19fd049a89b042bad7a3a286749b12c7"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Eli Lilly, EchoStar, Constellation Brands, and More",
    "summary": "U.S. equities were little changed at midday as the market had little news that would move stocks very much either way.",
    "url": "https://finnhub.io/api/news?id=b0afcc53e0eba1c0807275e1598fa00cb9459ee9b8977bc12eb4e1572062a060",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756223218,
      "headline": "Top Stock Movers Now: Eli Lilly, EchoStar, Constellation Brands, and More",
      "id": 136530068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "U.S. equities were little changed at midday as the market had little news that would move stocks very much either way.",
      "url": "https://finnhub.io/api/news?id=b0afcc53e0eba1c0807275e1598fa00cb9459ee9b8977bc12eb4e1572062a060"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Markets Flat Following Trump's Fed Governor Firing Post; Lutnick Signals Gov Stakes in Defense Companies",
    "summary": "The big three stock indexes were relatively flat in late-morning trading Tuesday, as investors looke",
    "url": "https://finnhub.io/api/news?id=38c43ebcb240f2161a0482a06986f06ef32f2288cbdf68a7c2dded0851604b49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756223209,
      "headline": "Top Midday Stories: Markets Flat Following Trump's Fed Governor Firing Post; Lutnick Signals Gov Stakes in Defense Companies",
      "id": 136530069,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The big three stock indexes were relatively flat in late-morning trading Tuesday, as investors looke",
      "url": "https://finnhub.io/api/news?id=38c43ebcb240f2161a0482a06986f06ef32f2288cbdf68a7c2dded0851604b49"
    }
  },
  {
    "ts": null,
    "headline": "Durable Goods Orders Decreased Less Than Expected",
    "summary": "Durable Goods Orders Decreased Less Than Expected",
    "url": "https://finnhub.io/api/news?id=4cdbc0b8b8d8277f0471411c23510e75f40900f2b8c32c12ef263bf21ec13bf0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756221420,
      "headline": "Durable Goods Orders Decreased Less Than Expected",
      "id": 136530071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Durable Goods Orders Decreased Less Than Expected",
      "url": "https://finnhub.io/api/news?id=4cdbc0b8b8d8277f0471411c23510e75f40900f2b8c32c12ef263bf21ec13bf0"
    }
  },
  {
    "ts": null,
    "headline": "Immuneering Stock Rises 21.7% on Supply Agreement With LLY",
    "summary": "IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.",
    "url": "https://finnhub.io/api/news?id=26b9173ae785ad84018db6b45b080e9c236697f037d16ab512b81424676aa4fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756221420,
      "headline": "Immuneering Stock Rises 21.7% on Supply Agreement With LLY",
      "id": 136530070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.",
      "url": "https://finnhub.io/api/news?id=26b9173ae785ad84018db6b45b080e9c236697f037d16ab512b81424676aa4fa"
    }
  },
  {
    "ts": null,
    "headline": "Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?",
    "summary": "NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.",
    "url": "https://finnhub.io/api/news?id=58676a204c00fe6820465d21057324d9da932526d4e40f02de1f31584f300d57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756220940,
      "headline": "Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?",
      "id": 136526731,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.",
      "url": "https://finnhub.io/api/news?id=58676a204c00fe6820465d21057324d9da932526d4e40f02de1f31584f300d57"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Investigational Obesity Drug Presents Major Revenue Opportunity, Truist Says",
    "summary": "Eli Lilly's (LLY) investigational oral drug orforglipron met its primary endpoint in a phase 3 trial",
    "url": "https://finnhub.io/api/news?id=efc018a15b4cfb12d0ee0a6230c6b1673f11b70cbacd1f1d572aea6eff6feb09",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756220741,
      "headline": "Eli Lilly's Investigational Obesity Drug Presents Major Revenue Opportunity, Truist Says",
      "id": 136530073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's (LLY) investigational oral drug orforglipron met its primary endpoint in a phase 3 trial",
      "url": "https://finnhub.io/api/news?id=efc018a15b4cfb12d0ee0a6230c6b1673f11b70cbacd1f1d572aea6eff6feb09"
    }
  },
  {
    "ts": null,
    "headline": "LLY obesity data seen as small sentiment hit for NVO, no major change—Barclays",
    "summary": "Investing.com -- Novo Nordisk shares may see limited pressure after Eli Lilly reported new trial results for its oral obesity treatment orforglipron, which Barclays said look more competitive with Wegovy in certain patients but do not alter the fundamental picture.",
    "url": "https://finnhub.io/api/news?id=afaf946a1e014bc105159903fdf4c8f0dd65ec357a13dead6bd43f19027baea0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756220137,
      "headline": "LLY obesity data seen as small sentiment hit for NVO, no major change—Barclays",
      "id": 136526736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Novo Nordisk shares may see limited pressure after Eli Lilly reported new trial results for its oral obesity treatment orforglipron, which Barclays said look more competitive with Wegovy in certain patients but do not alter the fundamental picture.",
      "url": "https://finnhub.io/api/news?id=afaf946a1e014bc105159903fdf4c8f0dd65ec357a13dead6bd43f19027baea0"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Stocks sink after Trump threatens Fed, overseas tech regulation",
    "summary": "Stocks are sinking in futures after a series of Trump Truth Social posts",
    "url": "https://finnhub.io/api/news?id=be4a9312348a90c3ea8860501ce30cfb685263607a12a92c94bfd956c710613b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756219840,
      "headline": "Stock Market Today: Stocks sink after Trump threatens Fed, overseas tech regulation",
      "id": 136530075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stocks are sinking in futures after a series of Trump Truth Social posts",
      "url": "https://finnhub.io/api/news?id=be4a9312348a90c3ea8860501ce30cfb685263607a12a92c94bfd956c710613b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's 'Surprising Development' In Obesity Just Slammed Viking, Novo Stocks",
    "summary": "Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful Phase 3 study.",
    "url": "https://finnhub.io/api/news?id=03a3adf0246d49e4662b5822c80d29a552133896fdb1047c314ea197e7e8285a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756218834,
      "headline": "Eli Lilly's 'Surprising Development' In Obesity Just Slammed Viking, Novo Stocks",
      "id": 136525631,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful Phase 3 study.",
      "url": "https://finnhub.io/api/news?id=03a3adf0246d49e4662b5822c80d29a552133896fdb1047c314ea197e7e8285a"
    }
  },
  {
    "ts": null,
    "headline": "Pre-Markets in Red but Improving on New Data",
    "summary": "We appear to be bouncing around a bit more in recent trading days after a steadier level following August 2nd lows.",
    "url": "https://finnhub.io/api/news?id=e043c7fb07e89ef813e70ffd1c03366df9f7f17c8c73805edcece63ae9243043",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756218720,
      "headline": "Pre-Markets in Red but Improving on New Data",
      "id": 136530076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We appear to be bouncing around a bit more in recent trading days after a steadier level following August 2nd lows.",
      "url": "https://finnhub.io/api/news?id=e043c7fb07e89ef813e70ffd1c03366df9f7f17c8c73805edcece63ae9243043"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s weight-loss pill meets target in key diabetes trial",
    "summary": "US pharmaceutical group Eli Lilly has announced that the latest trial of its anti-obesity pill has met weight-loss targets, boosting its plans...",
    "url": "https://finnhub.io/api/news?id=1ebaa1b19ffcde9127f5b8a508c46b4d288492e9775cc225199cc222ce4ef84c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756205109,
      "headline": "Eli Lilly’s weight-loss pill meets target in key diabetes trial",
      "id": 136525069,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US pharmaceutical group Eli Lilly has announced that the latest trial of its anti-obesity pill has met weight-loss targets, boosting its plans...",
      "url": "https://finnhub.io/api/news?id=1ebaa1b19ffcde9127f5b8a508c46b4d288492e9775cc225199cc222ce4ef84c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises as Firm Plans to Ask for Weight-Loss Pill Approval",
    "summary": "Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its experimental weight-loss pill.",
    "url": "https://finnhub.io/api/news?id=0249671821eba600685e2ead7612285d07b3c8de89911e5dca0017c2791c1b42",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756216301,
      "headline": "Eli Lilly Stock Rises as Firm Plans to Ask for Weight-Loss Pill Approval",
      "id": 136525633,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its experimental weight-loss pill.",
      "url": "https://finnhub.io/api/news?id=0249671821eba600685e2ead7612285d07b3c8de89911e5dca0017c2791c1b42"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Obesity Pill Moves Closer to Approval",
    "summary": "Eli Lilly & Co.'s experimental obesity pill helped patients lose 9.6% of their body weight in a trial that moves the company one step closer to a potential approval. Damian Garde has more on \"Bloomberg Open Interest.\"",
    "url": "https://finnhub.io/api/news?id=3fe5dd5c41052a7c5681f83f73df25ede117b3d05d1475935efb9a3d1ecd4ec2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756215709,
      "headline": "Eli Lilly's Obesity Pill Moves Closer to Approval",
      "id": 136525634,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Co.'s experimental obesity pill helped patients lose 9.6% of their body weight in a trial that moves the company one step closer to a potential approval. Damian Garde has more on \"Bloomberg Open Interest.\"",
      "url": "https://finnhub.io/api/news?id=3fe5dd5c41052a7c5681f83f73df25ede117b3d05d1475935efb9a3d1ecd4ec2"
    }
  },
  {
    "ts": null,
    "headline": "Interactive Brokers to join S&P 500, EchoStar & AT&T, Eli Lilly pill",
    "summary": "Allie Canal takes a closer look at some of the trading day's trending tickers, including Interactive Brokers (IBKR), EchoStar (SATS), AT&T (T), and Eli Lilly (LLY). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=187cb017f891cfd84d1b13f615965d4695aebf4c36cf3c621f308a848952d926",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756215460,
      "headline": "Interactive Brokers to join S&P 500, EchoStar & AT&T, Eli Lilly pill",
      "id": 136525635,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Allie Canal takes a closer look at some of the trading day's trending tickers, including Interactive Brokers (IBKR), EchoStar (SATS), AT&T (T), and Eli Lilly (LLY). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=187cb017f891cfd84d1b13f615965d4695aebf4c36cf3c621f308a848952d926"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Interactive Brokers, Talen Energy, Palantir, Nvidia, Serina Therapeutics, and More",
    "summary": "Interactive Brokers and Talen Energy trade higher following an announcement the stocks will be included in the S&P 500 index and S&P MidCap 400 index, respectively, beginning Thursday.",
    "url": "https://finnhub.io/api/news?id=55e2fa5acd533ed4c26e102d02d2913fb37c104798677b5e9b5b455c7c4bb1d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756201440,
      "headline": "These Stocks Are Moving the Most Today: Interactive Brokers, Talen Energy, Palantir, Nvidia, Serina Therapeutics, and More",
      "id": 136523769,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Interactive Brokers and Talen Energy trade higher following an announcement the stocks will be included in the S&P 500 index and S&P MidCap 400 index, respectively, beginning Thursday.",
      "url": "https://finnhub.io/api/news?id=55e2fa5acd533ed4c26e102d02d2913fb37c104798677b5e9b5b455c7c4bb1d8"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Edge Higher Premarket Tuesday",
    "summary": "Health care stocks were edging higher premarket Tuesday, with the Health Care Select Sector SPDR Fun",
    "url": "https://finnhub.io/api/news?id=892e54d573a6d5e3579a02a15473e41f7b4c6278b8990ee35780cff84f9134b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756213881,
      "headline": "Sector Update: Health Care Stocks Edge Higher Premarket Tuesday",
      "id": 136525197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were edging higher premarket Tuesday, with the Health Care Select Sector SPDR Fun",
      "url": "https://finnhub.io/api/news?id=892e54d573a6d5e3579a02a15473e41f7b4c6278b8990ee35780cff84f9134b1"
    }
  },
  {
    "ts": null,
    "headline": "Industry Leaders Transform Enterprise Data Centers for the AI Era With NVIDIA RTX PRO Servers",
    "summary": "NVIDIA RTX PRO Server NVIDIA RTX PRO Servers — a new category of enterprise data center infrastructure powered by the RTX PRO 6000 Blackwell Server Edition GPU. News Summary: Leading companies including Disney, Foxconn, Hitachi Ltd., Hyundai Motor Group, Lilly, SAP and TSMC are among the first to adopt NVIDIA RTX PRO Servers to speed AI reasoning, physical AI and business workloads.Enterprises are adopting NVIDIA RTX PRO Servers to transition from general-purpose clusters to AI factory infrastru",
    "url": "https://finnhub.io/api/news?id=40ca966a61afcc9665c9daeba325a2b0b4f64af8ada5bed1d26a6c1ab2813ec3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756213200,
      "headline": "Industry Leaders Transform Enterprise Data Centers for the AI Era With NVIDIA RTX PRO Servers",
      "id": 136525037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVIDIA RTX PRO Server NVIDIA RTX PRO Servers — a new category of enterprise data center infrastructure powered by the RTX PRO 6000 Blackwell Server Edition GPU. News Summary: Leading companies including Disney, Foxconn, Hitachi Ltd., Hyundai Motor Group, Lilly, SAP and TSMC are among the first to adopt NVIDIA RTX PRO Servers to speed AI reasoning, physical AI and business workloads.Enterprises are adopting NVIDIA RTX PRO Servers to transition from general-purpose clusters to AI factory infrastru",
      "url": "https://finnhub.io/api/news?id=40ca966a61afcc9665c9daeba325a2b0b4f64af8ada5bed1d26a6c1ab2813ec3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors",
    "summary": "Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes. In the trial, all three doses of orforglipron met the primary and all key secondary endpoints, delivering significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors at 72 weeks. With the completion of ATTAIN-2, Lilly now has the complete clinical data package required to i",
    "url": "https://finnhub.io/api/news?id=6209b4873ccf0ae1d7d64601250bde9720e71e2d6f6a128153842da9bbd6c545",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756212716,
      "headline": "Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors",
      "id": 136525639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes. In the trial, all three doses of orforglipron met the primary and all key secondary endpoints, delivering significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors at 72 weeks. With the completion of ATTAIN-2, Lilly now has the complete clinical data package required to i",
      "url": "https://finnhub.io/api/news?id=6209b4873ccf0ae1d7d64601250bde9720e71e2d6f6a128153842da9bbd6c545"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Tuesday: AMD, Eli Lilly, Interactive Brokers, Okta",
    "summary": "↗️ Advanced Micro Devices (AMD): The semiconductor powerhouse said it would collaborate with IBM (IBM) to develop next-generation computing architecture. AMD shares rose over 2.5% in premarket trading.",
    "url": "https://finnhub.io/api/news?id=f219782151fae5ac7c8c2e7a0815b14b7822ade3c5451906b7cb6fc5a589dda5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756211669,
      "headline": "Stocks to Watch Tuesday: AMD, Eli Lilly, Interactive Brokers, Okta",
      "id": 136525640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️ Advanced Micro Devices (AMD): The semiconductor powerhouse said it would collaborate with IBM (IBM) to develop next-generation computing architecture. AMD shares rose over 2.5% in premarket trading.",
      "url": "https://finnhub.io/api/news?id=f219782151fae5ac7c8c2e7a0815b14b7822ade3c5451906b7cb6fc5a589dda5"
    }
  },
  {
    "ts": null,
    "headline": "AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?",
    "summary": "Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.",
    "url": "https://finnhub.io/api/news?id=e9ae8a21897dd2166cd562557d9563a61343fc542a64763b6d02bc6364ea107b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756209960,
      "headline": "AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?",
      "id": 136525067,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.",
      "url": "https://finnhub.io/api/news?id=e9ae8a21897dd2166cd562557d9563a61343fc542a64763b6d02bc6364ea107b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals",
    "summary": "Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.",
    "url": "https://finnhub.io/api/news?id=ee3afe485d1638087577e58331696433253d671b6a8d42b982ae4d034c02a067",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756208040,
      "headline": "Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals",
      "id": 136525642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.",
      "url": "https://finnhub.io/api/news?id=ee3afe485d1638087577e58331696433253d671b6a8d42b982ae4d034c02a067"
    }
  },
  {
    "ts": null,
    "headline": "Lilly stock rises after weight loss drug succeeds in latest trial",
    "summary": "Investing.com -- Eli Lilly and Company (NYSE:LLY) stock rose in Tuesday premarket trading after the pharmaceutical giant announced positive results from a Phase 3 trial of its oral weight loss pill, paving the way for global regulatory submissions this year.",
    "url": "https://finnhub.io/api/news?id=dc5bb3fbcb6e02541cf92f8cddc2076fb1c6c4af174eb3be6f50a031512309b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756207890,
      "headline": "Lilly stock rises after weight loss drug succeeds in latest trial",
      "id": 136523882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Eli Lilly and Company (NYSE:LLY) stock rose in Tuesday premarket trading after the pharmaceutical giant announced positive results from a Phase 3 trial of its oral weight loss pill, paving the way for global regulatory submissions this year.",
      "url": "https://finnhub.io/api/news?id=dc5bb3fbcb6e02541cf92f8cddc2076fb1c6c4af174eb3be6f50a031512309b2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Says New Pill Results in 10.5% Weight-Loss for Diabetes Patients. The Stock Is Up.",
    "summary": "Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting.’",
    "url": "https://finnhub.io/api/news?id=cb6bbfc53efd6f4055394380b6dc4c0be15cba4c3c7efe9ef267f09030e8ce88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756207620,
      "headline": "Eli Lilly Says New Pill Results in 10.5% Weight-Loss for Diabetes Patients. The Stock Is Up.",
      "id": 136525068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting.’",
      "url": "https://finnhub.io/api/news?id=cb6bbfc53efd6f4055394380b6dc4c0be15cba4c3c7efe9ef267f09030e8ce88"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes. In the trial, all three doses of orforglipron met the primary and all key secondary endpoints, delivering significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors at 72 weeks. For the primary endpoint, orforglipron 36",
    "url": "https://finnhub.io/api/news?id=a16074dafd9d4d43329f4e613bb8cebffae69dc7800e904083224a908434abd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756205100,
      "headline": "Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity",
      "id": 136523883,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes. In the trial, all three doses of orforglipron met the primary and all key secondary endpoints, delivering significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors at 72 weeks. For the primary endpoint, orforglipron 36",
      "url": "https://finnhub.io/api/news?id=a16074dafd9d4d43329f4e613bb8cebffae69dc7800e904083224a908434abd0"
    }
  },
  {
    "ts": null,
    "headline": "Leqembi Or Blarcamesine For Alzheimer's Disease: Which One Is Better",
    "summary": "Anavex's Blarcamesine shows promise vs. Leqembi with better safety and ease.",
    "url": "https://finnhub.io/api/news?id=8bcdf440d667fc7d5cb8af92d9cbe31d149794a4057100d7b8d2c3eefea3710b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756198958,
      "headline": "Leqembi Or Blarcamesine For Alzheimer's Disease: Which One Is Better",
      "id": 136524891,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2118272364/image_2118272364.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Anavex's Blarcamesine shows promise vs. Leqembi with better safety and ease.",
      "url": "https://finnhub.io/api/news?id=8bcdf440d667fc7d5cb8af92d9cbe31d149794a4057100d7b8d2c3eefea3710b"
    }
  }
]